This phase III trial is looking at the safety and effectiveness of giving an immunotherapy (Durvalumab) in combination with chemotherapy (Gemcitabine and Cisplatin) in patients with muscle-invasive bladder cancer.
This trial is treating patients with muscle-invasive bladder cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer
Commercial Sponsor
AstraZeneca
Summary
Patients in this trial will be randomly assigned to receive chemotherapy plus Durvalumab as neoadjuvant treatment, or chemotherapy alone.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More